Envestnet Asset Management’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.01M Buy
106,809
+18,809
+21% +$180K ﹤0.01% 3626
2026
Q1
$803K Hold
88,000
﹤0.01% 3603
2025
Q4
$655K Hold
88,000
﹤0.01% 3521
2025
Q3
$589K Sell
88,000
-3,367
-4% -$23.4K ﹤0.01% 3637
2025
Q2
$605K Hold
91,367
﹤0.01% 3564
2025
Q1
$836K Sell
91,367
-287
-0.3% -$2.87K ﹤0.01% 3315
2024
Q4
$962K Buy
91,654
+214
+0.2% +$2.53K ﹤0.01% 3199
2024
Q3
$1.09M Buy
91,440
+73
+0.1% +$631 ﹤0.01% 3080
2024
Q2
$525K Hold
91,367
﹤0.01% 3430
2024
Q1
$475K Hold
91,367
﹤0.01% 3463
2023
Q4
$482K Hold
91,367
﹤0.01% 3344
2023
Q3
$302K Hold
91,367
﹤0.01% 3531
2023
Q2
$264K Buy
+91,367
New +$175K ﹤0.01% 3553
2022
Q4
Sell
-167,493
Closed -$1.17M 3958
2022
Q3
$1.17M Buy
167,493
+5,308
+3% +$41.6K ﹤0.01% 2440
2022
Q2
$1.11M Buy
162,185
+148,486
+1,084% +$1.52M ﹤0.01% 2506
2022
Q1
$193K Buy
13,699
+495
+4% +$6.63K ﹤0.01% 3699
2021
Q4
$191K Buy
+13,204
New +$188K ﹤0.01% 3669

Other funds holding BVS

Envestnet Asset Management's BVS Position: Q2 2026 in Review

Envestnet Asset Management increased its Bioventus (BVS) stake by 21% in Q2 2026, buying an estimated $180K and bringing the position to 106,809 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3626.

Envestnet Asset Management first reported a position in BVS in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.17M in Q3 2022. 157 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Envestnet Asset Management held 106,809 shares of Bioventus worth $1.01M as of Q2 2026.
  • Envestnet Asset Management bought 18,809 Bioventus shares in Q2 2026, an estimated $180K.
  • Bioventus made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3626 holding.
  • Envestnet Asset Management first reported a position in Bioventus in Q4 2021 and has held it in 17 quarters since.
  • Envestnet Asset Management's Bioventus position peaked at $1.17M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.